MANSFIELD, Mass.–(BUSINESS WIRE)–Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) has cleared SpiderFX® for the treatment of severely calcified lesions used in conjunction with plaque excision in arteries of the lower extremities. It is the only embolic protection device indicated for this treatment in the United States….
http://www.businesswire.com/news/home/20111201005183/en/Covidien%E2%80%99s-Embolic-Protection-Device-Receives-FDA-Clearance